Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company’s older diabetes treatment, Trulicity.
Breakdown
- Mounjaro reduced cardiovascular events by 8% compared to Trulicity in a phase three trial. 33s
- The drug also showed a 16% reduction in death from any cause versus Trulicity. 37s
- The trial met its goal of showing Mounjaro is not worse than Trulicity for heart health. 28s
- Some experts are concerned the results may not be strong enough to expand insurance coverage. 1m 3s
- Full trial results will be presented at a medical meeting for further evaluation. 1m 12s